$14.7 Billion is the total value of Laurion Capital Management LP's 426 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS INcl a | $32,187,653 | -13.5% | 4,825,735 | 0.0% | 0.22% | +25.9% | |
| KDNY | CHINOOK THERAPEUTICS INC | $19,208,713 | -11.6% | 829,750 | 0.0% | 0.13% | +28.4% | |
| VOR | VOR BIOPHARMA INC | $17,123,943 | -19.1% | 3,182,889 | 0.0% | 0.12% | +18.2% | |
| PYXIS ONCOLOGY INC | $12,714,920 | +199.3% | 3,170,803 | 0.0% | 0.09% | +335.0% | ||
| ALDX | ALDEYRA THERAPEUTICS INC | $9,502,017 | +42.7% | 956,900 | 0.0% | 0.06% | +109.7% | |
| PEPGEN INC | $8,127,031 | -8.5% | 664,516 | 0.0% | 0.06% | +31.0% | ||
| ANAB | ANAPTYSBIO INC | $5,727,406 | -29.8% | 263,208 | 0.0% | 0.04% | +2.6% | |
| ABOS | ACUMEN PHARMACEUTICALS INC | $4,898,585 | -24.8% | 1,206,548 | 0.0% | 0.03% | +10.0% | |
| SOLID BIOSCIENCES INC | $4,399,521 | -11.9% | 928,169 | 0.0% | 0.03% | +30.4% | ||
| SRRK | SCHOLAR ROCK HLDG CORP | $4,429,600 | -11.6% | 553,700 | 0.0% | 0.03% | +30.4% | |
| ICOSAVAX INC | $4,305,653 | -27.0% | 742,354 | 0.0% | 0.03% | +3.6% | ||
| MBACU | M3 BRIGADE ACQUISITION II COunit 99/99/9999 | $4,040,000 | +2.5% | 400,000 | 0.0% | 0.03% | +50.0% | |
| WVE | WAVE LIFE SCIENCES LTD | $3,773,595 | -38.1% | 871,500 | 0.0% | 0.03% | -10.3% | |
| ZIOP | ALAUNOS THERAPEUTICS INC | $3,603,915 | -2.9% | 5,720,500 | 0.0% | 0.02% | +47.1% | |
| LCTX | LINEAGE CELL THERAPEUTICS IN | $3,566,910 | +28.2% | 2,377,940 | 0.0% | 0.02% | +84.6% | |
| URGN | UROGEN PHARMA LTD | $3,516,744 | +4.2% | 380,600 | 0.0% | 0.02% | +50.0% | |
| KMPH | ZEVRA THERAPEUTICS INC | $3,141,600 | +19.8% | 571,200 | 0.0% | 0.02% | +75.0% | |
| ENTRADA THERAPEUTICS INC | $2,886,457 | +7.2% | 199,066 | 0.0% | 0.02% | +53.8% | ||
| RAIN | RAIN ONCOLOGY INC | $2,737,368 | +9.2% | 313,200 | 0.0% | 0.02% | +58.3% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $2,760,000 | -3.2% | 1,500,000 | 0.0% | 0.02% | +46.2% | |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | $2,131,060 | -37.4% | 83,900 | 0.0% | 0.02% | -6.2% | |
| CMPS | COMPASS PATHWAYS PLCsponsored ads | $1,880,812 | +23.7% | 189,407 | 0.0% | 0.01% | +85.7% | |
| IKNA | IKENA ONCOLOGY INC | $1,825,050 | +29.7% | 529,000 | 0.0% | 0.01% | +71.4% | |
| INZY | INOZYME PHARMA INC | $1,557,414 | +445.7% | 271,800 | 0.0% | 0.01% | +1000.0% | |
| PSTX | POSEIDA THERAPEUTICS INC | $1,680,756 | -41.9% | 545,700 | 0.0% | 0.01% | -21.4% | |
| ATOS | ATOSSA THERAPEUTICS INC | $1,613,482 | +37.2% | 2,225,800 | 0.0% | 0.01% | +120.0% | |
| THESEUS PHARMACEUTICALS INC | $1,595,017 | +78.3% | 179,619 | 0.0% | 0.01% | +175.0% | ||
| TRAVERE THERAPEUTICS INCnote 2.250% 3/0 | $1,472,175 | +7.8% | 1,500,000 | 0.0% | 0.01% | +66.7% | ||
| SCPH | SCPHARMACEUTICALS INC | $1,496,550 | +26.5% | 165,000 | 0.0% | 0.01% | +66.7% | |
| STTK | SHATTUCK LABS INC | $1,487,640 | +27.8% | 506,000 | 0.0% | 0.01% | +100.0% | |
| VIGIL NEUROSCIENCE INC | $1,274,658 | -21.7% | 130,200 | 0.0% | 0.01% | +12.5% | ||
| HOWL | WEREWOLF THERAPEUTICS INC | $1,359,540 | +26.8% | 522,900 | 0.0% | 0.01% | +80.0% | |
| VIRX | VIRACTA THERAPEUTICS INC | $1,109,820 | +8.9% | 698,000 | 0.0% | 0.01% | +60.0% | |
| CRDF | CARDIFF ONCOLOGY INC | $1,191,465 | +17.9% | 722,100 | 0.0% | 0.01% | +60.0% | |
| TSHA | TAYSHA GENE THERAPIES INC | $1,030,978 | -64.7% | 1,292,600 | 0.0% | 0.01% | -50.0% | |
| EDIT | EDITAS MEDICINE INC | $1,015,000 | -18.3% | 140,000 | 0.0% | 0.01% | +16.7% | |
| PRIME MEDICINE INC | $738,000 | -33.8% | 60,000 | 0.0% | 0.01% | 0.0% | ||
| BCAB | BIOATLA INC | $784,168 | -67.5% | 292,600 | 0.0% | 0.01% | -54.5% | |
| MBIO | MUSTANG BIO INC | $529,957 | -7.2% | 1,445,600 | 0.0% | 0.00% | +33.3% | |
| IONQ INC | $615,000 | +78.3% | 100,000 | 0.0% | 0.00% | +100.0% | ||
| MEIP | MEI PHARMA INC | $589,852 | -6.0% | 2,576,900 | 0.0% | 0.00% | +33.3% | |
| CYT | CYTEIR THERAPEUTICS INC | $654,290 | +10.3% | 359,500 | 0.0% | 0.00% | +33.3% | |
| TALS | TALARIS THERAPEUTICS INC | $561,033 | +84.3% | 298,422 | 0.0% | 0.00% | +300.0% | |
| TBLA | TABOOLA.COM LTD | $544,000 | -11.7% | 200,000 | 0.0% | 0.00% | +33.3% | |
| BCEL | ATRECA INC | $561,108 | +42.4% | 492,200 | 0.0% | 0.00% | +100.0% | |
| XILIO THERAPEUTICS INC | $454,422 | +18.2% | 142,900 | 0.0% | 0.00% | +50.0% | ||
| INNOVID CORP | $409,330 | -17.5% | 290,305 | 0.0% | 0.00% | +50.0% | ||
| DMY TECHNOLOGY GROUP INC VI | $511,005 | +1.7% | 50,000 | 0.0% | 0.00% | +50.0% | ||
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $367,883 | -22.6% | 21,401 | 0.0% | 0.00% | +50.0% | |
| MGTA | MAGENTA THERAPEUTICS INC | $462,754 | +101.2% | 582,300 | 0.0% | 0.00% | +200.0% | |
| CORSAIR PARTNERING CORP | $510,500 | +2.1% | 50,000 | 0.0% | 0.00% | +50.0% | ||
| SURF | SURFACE ONCOLOGY INC | $464,982 | -14.8% | 665,400 | 0.0% | 0.00% | 0.0% | |
| GLTO | GALECTO INC | $379,397 | +73.0% | 190,652 | 0.0% | 0.00% | +200.0% | |
| MXL | MAXLINEAR INC | $352,100 | +3.7% | 10,000 | 0.0% | 0.00% | 0.0% | |
| 9 METERS BIOPHARMA INC | $316,795 | +10.3% | 227,910 | 0.0% | 0.00% | +100.0% | ||
| SQZ | SQZ BIOTECHNOLOGIES CO | $241,584 | -24.3% | 431,400 | 0.0% | 0.00% | +100.0% | |
| CDAK | CODIAK BIOSCIENCES INC | $351,321 | -56.1% | 2,013,300 | 0.0% | 0.00% | -50.0% | |
| VALN | VALNEVA SEsponsored ads | $254,500 | -20.5% | 25,000 | 0.0% | 0.00% | +100.0% | |
| APLT | APPLIED THERAPEUTICS INC | $280,559 | +6.7% | 345,900 | 0.0% | 0.00% | +100.0% | |
| UNITY BIOTECHNOLOGY INC | $114,100 | -40.5% | 70,000 | 0.0% | 0.00% | 0.0% | ||
| IMPL | IMPEL PHARMACEUTICALS INC | $174,720 | -62.7% | 124,800 | 0.0% | 0.00% | -50.0% | |
| AMTI | APPLIED MOLECULAR TRANS INC | $154,112 | -23.8% | 481,600 | 0.0% | 0.00% | 0.0% | |
| OPT | OPTHEA LTDsponsored ads | $89,702 | -29.3% | 22,652 | 0.0% | 0.00% | 0.0% | |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $200,550 | -37.9% | 15,000 | 0.0% | 0.00% | -50.0% | |
| DMY TECHNOLOGY GROUP INC VI*w exp 99/99/999 | $1,990 | -24.2% | 25,000 | 0.0% | 0.00% | – | ||
| DBTX | DECIBEL THERAPEUTICS INC | $36,210 | +47.3% | 11,990 | 0.0% | 0.00% | – | |
| RIGETTI COMPUTING INC*w exp 99/99/999 | $1,197 | +44.6% | 10,000 | 0.0% | 0.00% | – | ||
| ERASCA INC | $69,531 | -30.2% | 23,100 | 0.0% | 0.00% | – | ||
| FNCH | FINCH THERAPEUTICS GROUP INC | $22,794 | -18.1% | 58,000 | 0.0% | 0.00% | – | |
| CORSAIR PARTNERING CORP*w exp 07/06/202 | $2,668 | -51.2% | 16,666 | 0.0% | 0.00% | – | ||
| FACTWS | FREEDOM ACQUISITION I CORP*w exp 03/02/202 | $3,136 | +25.5% | 12,500 | 0.0% | 0.00% | – | |
| INNOVID CORP*w exp 11/30/202 | $2,500 | -75.0% | 25,000 | 0.0% | 0.00% | – | ||
| TBLAW | TABOOLA.COM LTD*w exp 06/29/202 | $34,850 | -16.3% | 85,000 | 0.0% | 0.00% | – | |
| IONQ INC*w exp 10/01/202 | $35,500 | +95.0% | 25,000 | 0.0% | 0.00% | – | ||
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $30,665 | +130.0% | 16,666 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CME GROUP INC | 42 | Q3 2023 | 0.2% |
| CITIGROUP INC | 40 | Q3 2023 | 5.1% |
| CITIGROUP INC | 40 | Q3 2023 | 3.9% |
| MORGAN STANLEY | 39 | Q3 2023 | 1.3% |
| APPLE INC | 38 | Q3 2023 | 6.4% |
| JPMORGAN CHASE & CO | 38 | Q3 2023 | 3.6% |
| BK OF AMERICA CORP | 38 | Q3 2023 | 2.1% |
| JPMORGAN CHASE & CO | 38 | Q3 2023 | 2.3% |
| APPLE INC | 37 | Q3 2023 | 6.2% |
| BK OF AMERICA CORP | 37 | Q3 2023 | 2.2% |
View Laurion Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Codiak BioSciences, Inc. | March 03, 2023 | 3,713,300 | 9.6% |
| Pyxis Oncology, Inc. | February 08, 2023 | 3,170,803 | 9.0% |
| Research Alliance Corp. II | February 08, 2023 | ? | ? |
View Laurion Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G | 2024-02-08 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-03-03 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| SC 13G | 2023-02-08 |
View Laurion Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.